Compare Medpace Holdings Inc (MEDP) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Toyota Motor Corp — how do they compare? Medpace Holdings Inc trades at $534.38 (market cap $15.08B), while Toyota Motor Corp trades at $181.21 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 14.1× Medpace Holdings Inc's market cap, and Toyota Motor Corp pays a 3.51% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TM | |
|---|---|---|
Market Cap | $15.08B | $212.22B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $248.29 |
52-Week Low | $308.88 | $166.50 |
Enterprise Value | $14.55B | $376.42B |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Toyota Motor (TM) trades at $178.53, up 0.52% with neutral technical signals. The stock shows strong fundamentals with a low P/E of 9.73 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion announced July 6, 2026 (Reuters), signaling growth commitment. Cash flow trends show a 2025 dip but project recovery in 2026 with operating cash flow of $5.47 trillion.
Outlook is cautiously positive given undervaluation and hybrid vehicle demand, but risks include rising debt-to-asset ratios (41.29% in 2025) and margin pressure. Analyst consensus is mixed with 37.5% buy ratings, suggesting potential upside if execution aligns with expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
